Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.51 |
| ▸ | PLG | P00747 | 1/20 | 0.51 |
| ▸ | PLAU | P00749 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | HTR1D | P28221 | 2/20 | 0.42 |
| ▸ | HTR1B | P28222 | 2/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29957436 | 1.00 | CYP2A6 (0.58) | CYP2A6ALDH1A1MAPTKDM4EIMPDH2 | |
| SCHEMBL5403384 | 0.87 | ALDH1A1 (0.58) | CYP2A6ALDH1A1MAPTKDM4EIMPDH2 | |
| SCHEMBL23725271 | 0.83 | CYP2A6 (0.63) | CYP2A6ALDH1A1MAPTKDM4EIMPDH2 | |
| SCHEMBL7487153 | 0.81 | CYP2A6 (0.57) | CYP2A6ALDH1A1MAPTKDM4EIMPDH2 | |
| SCHEMBL29152827 | 0.80 | CYP2A6 (0.54) | CYP2A6ALDH1A1MAPTKDM4EIMPDH2 | |
| SCHEMBL2056399 | 0.80 | GABRA1 (0.56) | MAPTHTR1AHTR1DHTR1BGABRA1 | |
| SCHEMBL9006903 | 0.79 | HTR1D (0.54) | KIF11HTR1AHTR1DHTR1BGABRA1 | |
| SCHEMBL1049957 | 0.77 | PIM3 (0.65) | CYP2A6ALDH1A1MAPTKDM4EIMPDH2 | |
| SCHEMBL29935657 | 0.77 | PIM3 (0.65) | CYP2A6ALDH1A1MAPTKDM4EIMPDH2 | |
| SCHEMBL29957546 | 0.76 | ALDH1A1 (0.70) | CYP2A6ALDH1A1MAPTKDM4EIMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2661433-B1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | NOVARTIS AG (CH) | 2017-08-16 | — | — | EP | disclosed |
| EP-2661433-B1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | NOVARTIS AG (CH) | 2017-08-16 | — | — | EP | disclosed |
| US-9085555-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2015-07-21 | — | — | US | disclosed |
| US-9085555-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2015-07-21 | — | — | US | disclosed |
| US-9085555-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2015-07-21 | — | — | US | disclosed |
| CN-103402996-B | Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (AMD) | NOVARTIS AG | 2015-02-11 | — | — | CN | disclosed |
| CN-103402996-A | Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (AMD) | NOVARTIS AG | 2013-11-20 | — | — | CN | disclosed |
| EP-2661433-A1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | Novartis AG (CH) | 2013-11-13 | — | — | EP | disclosed |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2012-11-22 | — | — | US | disclosed |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2012-11-22 | — | — | US | disclosed |
| US-20110269779-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF OPHTHALMIC CONDITIONS | INTELLIKINE, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110077268-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-03-31 | — | — | US | disclosed |
| US-20100009963-A1 | KINASE ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-01-14 | — | — | US | disclosed |
| EP-0812825-B1 | PROPENONE DERIVATIVES | KYOWA HAKKO KOGYO KK (JP) | 2004-02-11 | — | — | EP | disclosed |
| EP-0680950-B1 | PROPENONE DERIVATIVES | KYOWA HAKKO KOGYO KK (JP) | 2001-05-23 | — | — | EP | disclosed |
| US-5952355-A | 1-ETHER-SUBSTITUTED PHENYL-3-INDOL-3-YL-2-PROPEN-1-ONE DERIVATIVES; ANTITUMOR AND -CARCINOGENIC AGENTS; IMMUNOSUPPRESSANTS; AUTOIMMUNE DISEASES; SIDE EFFECT REDUCTION | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1999-09-14 | — | — | US | disclosed |
| CN-1172476-A | Propenone derivatives | KYOWA HAKKO KOGYO KK (JP) | 1998-02-04 | — | — | CN | disclosed |
| EP-0812825-A1 | PROPENONE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1997-12-17 | — | — | EP | disclosed |
| EP-0770601-A1 | PROPENONE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1997-05-02 | — | — | EP | disclosed |
| EP-0680950-A1 | PROPENONE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1995-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009963-A1 | KINASE ANTAGONISTS | MTOR, RPS6KA3, AKT3 | CYP2A6 4562/4885ALDH1A1 4833/4885MAPT 2851/4885 |
| US-20110077268-A1 | KINASE INHIBITORS AND METHODS OF USE | MAP3K20, MAP3K1, PDPK1 | CYP2A6 4699/4885ALDH1A1 4739/4885MAPT 2921/4885 |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | C5, C3AR1, C9 | CYP2A6 493/4885ALDH1A1 2495/4885MAPT 4024/4885 |
| US-20110269779-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF OPHTHALMIC CONDITIONS | MTOR, PIK3C2B, PRKCH | CYP2A6 4717/4885ALDH1A1 4570/4885MAPT 1577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.